Patent ductus arteriosus management and the drift towards therapeutic nihilism–What is the evidence?

K de Waal, R Prasad, M Kluckow - Seminars in Fetal and Neonatal …, 2021 - Elsevier
The published literature on patent ductus arteriosus (PDA) management is challenging to
interpret due to poorly designed trials with high rates of open label treatments …

Impact of patent ductus arteriosus shunt size and duration on risk of death or severe respiratory morbidity in preterm infants born in China

Y Deng, H Zhang, Z Zhao, J Du, R Bai… - European journal of …, 2022 - Springer
The purpose of this study is to assess whether duration and size of the arterial duct were
associated with severe respiratory morbidity and mortality in preterm infants. All …

An observational, prospective, multicenter, registry-based cohort study comparing conservative and medical management for patent ductus arteriosus

E Okulu, O Erdeve, Z Arslan, N Demirel, H Kaya… - Frontiers in …, 2020 - frontiersin.org
No consensus has been reached on which patent ductus arteriosus (PDAs) in preterm
infants require treatment and if so, how, and when they should be treated. A prospective …

Impact of cerebral oxygen saturation monitoring on short-term neurodevelopmental outcomes in neonates with encephalopathy-a prospective Cohort study

VV Tewari, A Kumar, A Kurup, H Daryani… - Current Pediatric …, 2022 - ingentaconnect.com
Background: Near-infrared spectroscopy (NIRS) has been used for monitoring cerebral
oxygen saturation (rSO2) in neonates. There is a lack of data from low-middle income …

Evaluation of the association between patent ductus arteriosus approach and neurodevelopment in extremely preterm infants

SB Cervera, S Saeed, TM Luu, A Gorgos… - Journal of …, 2024 - nature.com
Objective Assess if unit-level PDA management correlates with neurodevelopmental
impairment (NDI) at 18–24 months corrected postnatal age (CPA) in extremely preterm …

Conservative treatment without any intervention compared with other therapeutic strategies for symptomatic patent ductus arteriosus in extremely preterm infants: a …

J Shin, JA Lee, S Oh, EH Lee, BM Choi - Frontiers in Pediatrics, 2021 - frontiersin.org
Objective: Although symptomatic treatment is the most preferred treatment strategy for
proven symptomatic patent ductus arteriosus (PDA), a considerable number of infants only …

Aminoglycosides were associated with higher rates of surgical patent ductus arteriosus closure in preterm infants

J Marissen, H Erdmann, K Böckenholt… - Acta …, 2021 - Wiley Online Library
Aim In animal studies, aminoglycosides induced ductus arteriosus relaxation in a dose‐
dependent fashion. We tested the hypothesis that antibiotic treatment of preterm infants with …

Evaluation of the association between patent ductus arteriosus approach and neurodevelopment in extremely preterm infants

G Altit, B Soledad, S Saeed, A Gorgos, M Beltempo… - 2023 - researchsquare.com
Objective Assess if unit-level PDA management correlates with neurodevelopmental
impairment (NDI) at 18–24 months corrected gestational age (cGA) in extremely preterm …

An Observational, Prospective, Multicenter, Registry-Based Cohort Study Comparing Conservative and Medical Management for Patent Ductus Arteriosus

V Bhandari, J Slaughter, EA Jensen… - … of Patent Ductus …, 2021 - books.google.com
Okulu et al. Conservative vs. Medical Management of PDA differences in the rates of late-
onset sepsis, necrotizing enterocolitis (NEC), retinopathy of prematurity, intraventricular …